SCHEMBL1329288

SCHEMBL1329288

CCc1cccc(CC)c1-c1cc(Oc2ccc3c(c2)OCCO3)c(CN2CCc3ccccc3C2)c(C)n1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
C5AR1 P21730 1/20 0.41
LMNA P02545 2/20 0.41
PRMT5 O14744 3/20 0.40
WDR77 Q9BQA1 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 2/20 0.40
TP53 P04637 2/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1327907 0.85 C5AR1 (0.48) MAPTC5AR1LMNAALDH1A1MAPK1
SCHEMBL1327445 0.84 C5AR1 (0.42) MAPTC5AR1LMNAPRMT5WDR77
SCHEMBL2141591 0.84 L3MBTL1 (0.43) MAPTC5AR1LMNAPRMT5WDR77
SCHEMBL1327932 0.83 C5AR1 (0.41) MAPTC5AR1LMNAPRMT5WDR77
SCHEMBL2140546 0.83 PRMT5 (0.43) C5AR1LMNAPRMT5WDR77KDM4E
SCHEMBL1327975 0.83 MEN1 (0.48) C5AR1LMNAPRMT5WDR77KDM4E
SCHEMBL2139159 0.83 C5AR1 (0.39) C5AR1LMNAALDH1A1MAPK1HPGD
SCHEMBL1329410 0.83 C5AR1 (0.54) MAPTC5AR1LMNAALDH1A1MAPK1
SCHEMBL2138901 0.82 MEN1 (0.48) MAPTC5AR1LMNAALDH1A1MAPK1
SCHEMBL1327169 0.82 MAOB (0.42) MAPTC5AR1LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 MAPT 4726/4885C5AR1 2/4885LMNA 3672/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 MAPT 4726/4885C5AR1 2/4885LMNA 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.